CinCor Pharma
Cincinnati
About CinCor Pharma
CinCor is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval. CinCor’s focus is on cardiovascular, metabolic and kidney diseases. CinCor has program is CIN-107, a novel aldosterone synthase inhibitor.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $418.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Aug 2022)
- Ticker: nasdaq:CINC
- Website: cincor.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cincor-pharma-2458 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.